These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 9340883)

  • 1. [Cystic fibrosis and chronic Pseudomonas aeruginosa infection. Possibilities for immunologic prophylaxis and therapy].
    Bisgaard AT; Petersen RH
    Ugeskr Laeger; 1997 Sep; 159(39):5786-90. PubMed ID: 9340883
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Early aggressive eradication therapy for intermittent Pseudomonas aeruginosa airway colonization in cystic fibrosis patients: 15 years experience.
    Hansen CR; Pressler T; Høiby N
    J Cyst Fibros; 2008 Nov; 7(6):523-30. PubMed ID: 18693078
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antibody response to Pseudomonas aeruginosa in children with cystic fibrosis.
    Milagres LG; Castro TL; Garcia D; Cruz AC; Higa L; Folescu T; Marques EA
    Pediatr Pulmonol; 2009 Apr; 44(4):392-401. PubMed ID: 19283764
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pseudomonas aeruginosa chromosomal beta-lactamase in patients with cystic fibrosis and chronic lung infection. Mechanism of antibiotic resistance and target of the humoral immune response.
    Ciofu O
    APMIS Suppl; 2003; (116):1-47. PubMed ID: 14692154
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vaccination promotes TH1-like inflammation and survival in chronic Pseudomonas aeruginosa pneumonia. A new prophylactic principle.
    Johansen HK; Cryz SJ; Hougen HP; Moser C; Høiby N
    Behring Inst Mitt; 1997 Feb; (98):269-73. PubMed ID: 9382750
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Eradication of early Pseudomonas aeruginosa infection.
    Høiby N; Frederiksen B; Pressler T
    J Cyst Fibros; 2005 Aug; 4 Suppl 2():49-54. PubMed ID: 16023416
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prophylactic antibiotics in cystic fibrosis: a conviction without evidence?
    Smyth A
    Pediatr Pulmonol; 2005 Dec; 40(6):471-6. PubMed ID: 16200640
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The clonal antibody response to Pseudomonas aeruginosa heat shock protein is highly diverse in cystic fibrosis patients.
    Ulanova M; Petersen TD; Ciofu O; Jensen P; Hahn-Zoric M; Hanson LA; Høiby N
    APMIS; 1997 Jun; 105(6):449-56. PubMed ID: 9236862
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Eradication of early Pseudomonas infection in cystic fibrosis.
    Lee TW
    Chron Respir Dis; 2009; 6(2):99-107. PubMed ID: 19411571
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pseudomonas aeruginosa chronic colonization in cystic fibrosis patients.
    Murray TS; Egan M; Kazmierczak BI
    Curr Opin Pediatr; 2007 Feb; 19(1):83-8. PubMed ID: 17224667
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A multicenter vaccine trial using the Pseudomonas aeruginosa flagella vaccine IMMUNO in patients with cystic fibrosis.
    Döring G; Dorner F
    Behring Inst Mitt; 1997 Feb; (98):338-44. PubMed ID: 9382758
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Approaches to the treatment of initial Pseudomonas aeruginosa infection in children who have cystic fibrosis.
    Lahiri T
    Clin Chest Med; 2007 Jun; 28(2):307-18. PubMed ID: 17467550
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Passive immunotherapy for treatment of endobronchitis in cystic fibrosis].
    Moss RB
    Infusionsther Transfusionsmed; 1993 Apr; 20 Suppl 1():42-6; discussion 47. PubMed ID: 8499750
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antimicrobial therapy for pulmonary pathogenic colonisation and infection by Pseudomonas aeruginosa in cystic fibrosis patients.
    Cantón R; Cobos N; de Gracia J; Baquero F; Honorato J; Gartner S; Alvarez A; Salcedo A; Oliver A; García-Quetglas E;
    Clin Microbiol Infect; 2005 Sep; 11(9):690-703. PubMed ID: 16104983
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prophylaxis and therapy of Pseudomonas aeruginosa infection in cystic fibrosis and immunocompromised patients.
    Lang AB; Horn MP; Imboden MA; Zuercher AW
    Vaccine; 2004 Dec; 22 Suppl 1():S44-8. PubMed ID: 15576201
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rationale for development of immunotherapies that target mucoid Pseudomonas aeruginosa infection in cystic fibrosis patients.
    Pier GB
    Behring Inst Mitt; 1997 Feb; (98):350-60. PubMed ID: 9382760
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Novel therapeutic possibilities in cystic fibrosis].
    Kilian K; Kisiel BM
    Pol Merkur Lekarski; 2006 May; 20(119):586-90. PubMed ID: 16875169
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antibody response to Pseudomonas aeruginosa in cystic fibrosis patients: a marker of therapeutic success?--A 30-year cohort study of survival in Danish CF patients after onset of chronic P. aeruginosa lung infection.
    Johansen HK; Nørregaard L; Gøtzsche PC; Pressler T; Koch C; Høiby N
    Pediatr Pulmonol; 2004 May; 37(5):427-32. PubMed ID: 15095326
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fcgamma receptor IIA genotype and susceptibility to P. aeruginosa infection in patients with cystic fibrosis.
    De Rose V; Arduino C; Cappello N; Piana R; Salmin P; Bardessono M; Goia M; Padoan R; Bignamini E; Costantini D; Pizzamiglio G; Bennato V; Colombo C; Giunta A; Piazza A
    Eur J Hum Genet; 2005 Jan; 13(1):96-101. PubMed ID: 15367919
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Towards zero prevalence of chronic Pseudomonas aeruginosa infection in children with cystic fibrosis.
    Lebecque P; Leal T; Zylberberg K; Reychler G; Bossuyt X; Godding V
    J Cyst Fibros; 2006 Dec; 5(4):237-44. PubMed ID: 16790367
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.